Catalyst Pharmaceutical Partners, Inc. Closes Previously Announced $15.1 Million Registered Direct Offering

Catalyst Pharmaceutical Partners, Inc. Closes Previously Announced $15.1
Million Registered Direct Offering

CORAL GABLES, Fla., Sept. 10, 2013 (GLOBE NEWSWIRE) -- Catalyst Pharmaceutical
Partners, Inc. (Nasdaq:CPRX) today reported that it has closed its previously
announced offering of 8.8 million shares of its common stock in a registered
direct public offering. The offering price was $1.72 per share, resulting in
gross proceeds of approximately $15.1 million. Roth Capital Partners acted as
the exclusive placement agent for the offering and Aegis Capital Corp., Maxim
Group LLC and H.C. Wainwright & Co. acted as financial advisers with respect
to the offering.

Patrick J. McEnany, Catalyst's Chairman and CEO, stated: "We are pleased to
have completed this financing, which we believe, along with the proceeds from
recent warrant exercises, gives us the capital necessary to fund development
of Firdapse™ and allows us to begin new clinical studies for CPP-115." Mr.
McEnany continued: "We are also excited that several high quality fundamental
life science investors, including New Leaf Venture Partners, participated in
our offering."

Dr. Mark G. Charest of New Leaf Venture Partners, stated: "New Leaf is pleased
to support the development of Firdapse™ under the recently granted
'Breakthrough Therapy Designation.' We are excited about the potential for

The shares were offered pursuant to a shelf registration statement on Form S-3
(File No. 333-170945) filed pursuant to the Securities Act of 1933, as
amended, which was previously filed with, and declared effective by, the
Securities and Exchange Commission (SEC). A prospectus supplement relating to
the offering has been filed with the SEC and is available on the SEC's website

This press release does not and shall not constitute an offer to sell or the
solicitation of an offer to buy, nor shall there be any sale of these
securities in any state or jurisdiction in which such offer, solicitation or
sale would be unlawful prior to registration or qualification under the
securities laws of any such state or jurisdiction.

About Catalyst Pharmaceutical Partners

Catalyst Pharmaceutical Partners, Inc. is a specialty pharmaceutical company
focused on the development and commercialization of novel prescription drugs
targeting rare (orphan) neuromuscular and neurological diseases, including
Lambert-Eaton Myasthenic Syndrome (LEMS), infantile spasms, and Tourette
Syndrome. Catalyst's lead candidate, Firdapse™ for the treatment of LEMS, is
currently undergoing testing in a global, multi-center, pivotal phase III
trial and recently received "Breakthrough Therapy Designation" from the U.S.
Food & Drug Administration (FDA). Catalyst is also developing a potentially
safer and more potent vigabatrin analog (designated CPP-115) to treat
infantile spasms, and epilepsy, as well as other neurological conditions
associated with reduced GABAergic signaling, like post-traumatic stress
disorder and Tourette Syndrome.

Forward-Looking Statements

This press release contains forward-looking statements. Forward-looking
statements involve known and unknown risks and uncertainties, which may cause
Catalyst's actual results in future periods to differ materially from
forecasted results. A number of factors, including the timing of completion of
Catalyst's currently ongoing Phase III trial of Firdapse™, whether the Phase
III trial will be successful, whether the receipt of breakthrough therapy
designation for Firdapse™ will expedite the development and review of
Firdapse™ by the FDA or the likelihood that the product will be found to be
safe and effective, whether the proceeds of this offering, along with the
proceeds of recent warrant exercises, will be sufficient to fund the
development of Firdapse™ and to begin new clinical studies for CPP-115,
whether an NDA for Firdapse™ will ever be accepted for filing by the FDA, the
timing of any such NDA filing or acceptance, whether, even if approved,
Firdapse™ will be the only approved treatment option for LEMS patients,
whether any of Catalyst's product candidates will ever be approved for
commercialization or successfully commercialized, and those other factors
described in Catalyst's Annual Report on Form 10-K for the fiscal year 2012
and other filings with the U.S. Securities and Exchange Commission (SEC),
could adversely affect Catalyst. Copies of Catalyst's filings with the SEC are
available from the SEC, may be found on Catalyst's website or may be obtained
upon request from Catalyst. Catalyst does not undertake any obligation to
update the information contained herein, which speaks only as of this date.

CONTACT: For Further Information Contact:
         Patrick McEnany
         Catalyst Pharmaceutical Partners
         Chief Executive Officer
         (305) 529-2522
         Melody Carey
         Rx Communications Group
         (917) 322-2571
Press spacebar to pause and continue. Press esc to stop.